Biostage Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $5.07
- Today's High:
- $5.12
- Open Price:
- $5.12
- 52W Low:
- $4.3
- 52W High:
- $9
- Prev. Close:
- $4.95
- Volume:
- 321
Company Statistics
- Market Cap.:
- $66.08 million
- Book Value:
- -0.084
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -99.61%
- Return on Equity TTM:
- -492.28%
Company Profile
Biostage Inc had its IPO on under the ticker symbol BSTG.
The company operates in the Healthcare sector and Biotechnology industry. Biostage Inc has a staff strength of 7 employees.
Stock update
Shares of Biostage Inc opened at $5.12 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $5.07 - $5.12, and closed at $5.12.
This is a +3.43% increase from the previous day's closing price.
A total volume of 321 shares were traded at the close of the day’s session.
In the last one week, shares of Biostage Inc have increased by +4.49%.
Biostage Inc's Key Ratios
Biostage Inc has a market cap of $66.08 million, indicating a price to book ratio of 28.4738 and a price to sales ratio of 0.
In the last 12-months Biostage Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-6727000. The EBITDA ratio measures Biostage Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Biostage Inc’s operating margin was 0% while its return on assets stood at -99.61% with a return of equity of -492.28%.
In Q1, Biostage Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Biostage Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-0.54 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Biostage Inc’s profitability.
Biostage Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -7.4891. Its price to sales ratio in the trailing 12-months stood at 0.
Biostage Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $4.34 million
- Total Liabilities
- $1.33 million
- Operating Cash Flow
- $-9000.00
- Capital Expenditure
- $9000
- Dividend Payout Ratio
- 0%
Biostage Inc ended 2024 with $4.34 million in total assets and $0 in total liabilities. Its intangible assets were valued at $4.34 million while shareholder equity stood at $-1062000.00.
Biostage Inc ended 2024 with $0 in deferred long-term liabilities, $1.33 million in other current liabilities, 127000.00 in common stock, $-85901000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $3.27 million and cash and short-term investments were $3.27 million. The company’s total short-term debt was $0 while long-term debt stood at $0.
Biostage Inc’s total current assets stands at $3.63 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $1.23 million and inventory worth $0.
In 2024, Biostage Inc's operating cash flow was $-9000.00 while its capital expenditure stood at $9000.
Comparatively, Biostage Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $5.12
- 52-Week High
- $9
- 52-Week Low
- $4.3
- Analyst Target Price
- $
Biostage Inc stock is currently trading at $5.12 per share. It touched a 52-week high of $9 and a 52-week low of $9. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $4.24 and 200-day moving average was $5.47 The short ratio stood at 3.35 indicating a short percent outstanding of 0%.
Around 5358.8% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About Biostage Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Biostage, Inc., a biotechnology company, offers products to cure patients of cancers, injuries, and birth defects of the gastro-intestinal tract and the airways. The company’s pipeline includes organ-regeneration technology for the repair or replacement of diseased or damaged organs, as well as product candidates to treat cancer, injury, and birth defects of the bronchus. Its lead product candidate is Biostage Esophageal Implant for the treatment of severe esophageal disease. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2009 and is headquartered in Holliston, Massachusetts.